NY-METLIFE
15.10.2020 11:02:06 CEST | Business Wire | Press release
MetLife, Inc. (NYSE: MET) today announced a number of changes to its senior leadership team. All changes are effective on January 1, 2021, unless otherwise noted.
Executive Vice President and President of the Latin America region Oscar Schmidt will retire after a distinguished 26-year career with the company. He will step away from his executive position on December 31, 2020, and will stay on through the end of March 2021 to assist with the leadership transition.
“Over the past two and a half decades, Oscar has helped us grow and develop our Latin America business, building a well-diversified portfolio of businesses across the region,” said MetLife President and CEO Michel Khalaf. “Under his strong leadership, we have grown to become the largest life insurer in Latin America – a distinction achieved organically and through a number of acquisitions.”
Succeeding Schmidt as Regional President, Latin America, will be Eric Clurfain , Executive Vice President and Chairman, President and CEO of MetLife Japan K.K., subject to the necessary approvals. He will report to Khalaf.
“With more than two decades of insurance experience, Eric has a proven track record of building high-performing teams and businesses and a deep commitment to our associates and customers,” Khalaf said. “Over the past two years, his intense focus on business execution and customer centricity has driven culture change in Japan and delivered strong results in support of our Next Horizon strategy. Under his leadership, I am confident LatAm will continue to be a growth engine for MetLife.”
Clurfain’s career path has spanned numerous geographies and strategic leadership responsibilities. Prior to his current role, Clurfain was Regional Head for EMEA with oversight over the region’s 25 markets. Previously, he was Regional Head for Central and Eastern Europe after serving as General Manager of MetLife in Turkey. Earlier in his career with AIG/Alico, Clurfain lived and worked in Latin America.
Succeeding Clurfain as Executive Vice President and Chairman, President and CEO of MetLife Japan K.K. will be Dirk Ostijn , Head of EMEA, subject to the necessary approvals. Ostijn will report to Executive Vice President Kishore Ponnavolu , Regional President, Asia.
“Dirk has successfully led our EMEA region through a challenging operating environment,” Khalaf said. “Under his leadership, the EMEA team built strong momentum with a robust pipeline of new business opportunities, a relentless focus on efficiency, and a diversified model spanning more than 25 markets. I know his exemplary leadership, deep insurance expertise, and passion for the customer will be welcomed and appreciated by our team in Japan.”
With more than 30 years of experience, Ostijn’s career encompasses all aspects of the life insurance industry, including product, finance, operations, customer service and technology. He also spent more than a decade managing insurance brokerage operations, served as a General Manager in Belgium and held regional roles such as chief financial officer and head of strategic initiatives.
Succeeding Ostijn as Head of EMEA will be Nuria Garcia , Senior Vice President and Deputy Head of EMEA. She will report to Khalaf.
“Nuria has a strong focus on business development and partnerships as well as a passion for the customer,” Khalaf said. “She is a highly effective leader who can connect internal and external stakeholders to collaborate across business, function and market. Her leadership played an integral role in the region’s continued strong performance, and I have every confidence that she will continue to build on this track record going forward.”
Garcia has more than 20 years of experience in EMEA spanning distribution, marketing, operations and finance, both with MetLife and GE.
“Taken together, these moves demonstrate not only our commitment to talent development and succession planning, but our deep bench of leaders who are ready to step up immediately and deliver value to our customers and shareholders,” Khalaf said.
About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates ("MetLife"), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help its individual and institutional customers navigate their changing world. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com .
Forward-Looking Statements
The forward-looking statements in this disclosure, using words such as “will,” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it has no obligation to correct or update any of these statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201015005425/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release
Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
